Compare KGS & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KGS | RGEN |
|---|---|---|
| Founded | 2011 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.6B |
| IPO Year | 2023 | 1995 |
| Metric | KGS | RGEN |
|---|---|---|
| Price | $64.92 | $146.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $57.17 | ★ $167.67 |
| AVG Volume (30 Days) | ★ 1.7M | 947.4K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | 58.93 | ★ 286.96 |
| EPS | ★ 0.20 | 0.15 |
| Revenue | ★ $1,308,100,000.00 | $141,236,000.00 |
| Revenue This Year | $12.30 | $14.30 |
| Revenue Next Year | $7.96 | $14.52 |
| P/E Ratio | ★ $330.00 | $988.07 |
| Revenue Growth | 12.83 | ★ 35.10 |
| 52 Week Low | $30.06 | $100.99 |
| 52 Week High | $77.68 | $175.77 |
| Indicator | KGS | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 41.39 | 62.57 |
| Support Level | $55.10 | $141.44 |
| Resistance Level | $77.13 | $149.05 |
| Average True Range (ATR) | 2.99 | 5.08 |
| MACD | -0.58 | 0.16 |
| Stochastic Oscillator | 11.50 | 75.28 |
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. The company manages its business through two operating segments: Contract Services and Other Services. Contract Services consists of operating company-owned and customer-owned compression, gas treating, and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings. Maximum revenue for the company is generated from its Contract Services segment.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.